Serotonin transporter genetic variation and antidepressant response and tolerability: a systematic review and meta-analysis

Please always quote using this URN: urn:nbn:de:bvb:20-opus-252294
  • Antidepressants are used to treat several psychiatric disorders; however, a large proportion of patients do not respond to their first antidepressant therapy and often experience adverse drug reactions (ADR). A common insertion–deletion polymorphism in the promoter region (5-HTTLPR) of the serotonin transporter (SLC6A4) gene has been frequently investigated for its association with antidepressant outcomes. Here, we performed a systematic review and meta-analysis to assess 5-HTTLPR associations with antidepressants: (1) response in psychiatricAntidepressants are used to treat several psychiatric disorders; however, a large proportion of patients do not respond to their first antidepressant therapy and often experience adverse drug reactions (ADR). A common insertion–deletion polymorphism in the promoter region (5-HTTLPR) of the serotonin transporter (SLC6A4) gene has been frequently investigated for its association with antidepressant outcomes. Here, we performed a systematic review and meta-analysis to assess 5-HTTLPR associations with antidepressants: (1) response in psychiatric disorders other than major depressive disorder (MDD) and (2) tolerability across all psychiatric disorders. Literature searches were performed up to January 2021, yielding 82 studies that met inclusion criteria, and 16 of these studies were included in the meta-analyses. Carriers of the 5-HTTLPR LL or LS genotypes were more likely to respond to antidepressant therapy, compared to the SS carriers in the total and European ancestry-only study populations. Long (L) allele carriers taking selective serotonin reuptake inhibitors (SSRIs) reported fewer ADRs relative to short/short (SS) carriers. European L carriers taking SSRIs had lower ADR rates than S carriers. These results suggest the 5-HTTLPR polymorphism may serve as a marker for antidepressant outcomes in psychiatric disorders and may be particularly relevant to SSRI treatment among individuals of European descent.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Kiera Stein, Abdullah Al Maruf, Daniel J. Müller, Jeffrey R. Bishop, Chad A. Bousman
URN:urn:nbn:de:bvb:20-opus-252294
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie
Language:English
Parent Title (English):Journal of Personalized Medicine
ISSN:2075-4426
Year of Completion:2021
Volume:11
Issue:12
Article Number:1334
Source:Journal of Personalized Medicine (2021) 11:12, 1334. https://doi.org/10.3390/jpm11121334
DOI:https://doi.org/10.3390/jpm11121334
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:5-HTTLPR; SLC6A4; antidepressant; efficacy; genotype; pharmacogenetics; tolerability
Release Date:2023/05/26
Date of first Publication:2021/12/09
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International